



ThermoGenesis Corp. Receives Health Canada Regulatory License To Market Autologous Thrombin Processing Device™ (TPD)

RANCHO CORDOVA, Calif., April 25, 2006/PRNewswire-FirstCall/ -- **ThermoGenesis Corp. (NASDAQ: KOOL)** announced today that the Medical Devices Bureau of Health Canada has issued ThermoGenesis a license to market the Company's TPD, a small, handheld, disposable device that produces thrombin from a patient's own plasma in less than 30 minutes. In accordance with Health Canada's Medical Device Regulations the license allows Biomet, Inc. and Medtronic, Inc., ThermoGenesis' non-exclusive global distributors for the TPD, the right to begin sales and marketing efforts in Canada.

"Canada's regulatory approval further validates the TPD platform, which offers patients the safety of autologous thrombin," said Kevin Simpson, President and Chief Operating Officer of ThermoGenesis Corp. "With Biomet and Medtronic currently marketing the TPD in Europe, this marketing license from Canadian regulatory authorities will allow ThermoGenesis and our distribution partners to further penetrate the \$180 million global thrombin market."

Regulatory Status of TPD

The TPD as a stand alone product has been CE Marked and is currently marketed in Europe by Biomet, Inc. subsidiary Cell Factor Technologies, Inc., Medtronic, Inc. in conjunction with their platelet gel products and independent distributors. From a marketing perspective, the CE Mark is the European equivalent to a U.S. Food and Drug Administration (FDA) approval, in that it allows the Company to sell the TPD throughout the European community.

Global Thrombin Market

The global thrombin market, estimated at \$180 million per year, is currently dominated by thrombin sourced from bovine (cow) blood. Surgeons use bovine-derived thrombin to stop minor bleeding during surgery and to release growth factors from concentrated autologous platelets (platelet gels) inserted into wound sites to accelerate healing of bone and tissue. However, bovine-derived thrombin can create cross-reactive anti-bovine antibodies that cause allergic reaction and inhibit blood clotting in humans, which can cause post-operative hemorrhage in a subsequent operation¹.

1 Ortel et al. "Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin." Ann Surg. 2001 Jan;233(1):88-96.

About ThermoGenesis Corp.

ThermoGenesis Corp. is a leader in developing and manufacturing automated blood processing systems and disposables that enable the manufacture, preservation and delivery of cell and tissue therapy products.

- **The BioArchive® System**, an automated cryogenic device, is used by cord blood stem cell banks in 29 countries for cryopreserving and archiving cord blood stem cell units for transplant.
- **The AutoXpress™ System**, is a newly developed semi-automated device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood.
- **The CryoSeal® FS System**, an automated device and companion sterile blood processing disposable, is used to prepare fibrin sealants from plasma in about an hour. Enrollment in a 150-patient U.S. pivotal clinical trial has been completed and a PMA is being reviewed by the FDA.
- **The Thrombin Processing Device™ (TPD™)** is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of plasma in less than 30 minutes. The TPD market launch is underway in Europe.

This press release, including statements regarding financial information for future periods, contain forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2006, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2006. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward looking statements.

For More Information, Contact:

THERMOGENESIS CORP.
Matthew Plavan: (916) 858-5100
Or Fern Lazar (212) 867-1762

or visit the web site at www.thermogenesis.com